Infertility Clinical Trial
— HCGOfficial title:
The Role of Low Dose HCG in Improving the Quality of Antagonist Protocol in Patient Undergoing ICSI
Verified date | February 2015 |
Source | Cairo University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A novel gonadotropin protocol for ovarian stimulation adds low-dose hCG (50- 200 IU) as a
source of LH (luteinizing hormone) in the late follicular phase .
This regimen reduces the number of small pre-ovulatory follicles which could reduce the risk
of OHSS(ovarian hyper stimulation syndrome). Adequate ovarian hormonal levels , oocyte
maturation, avoidance of a premature LH surge, and increased pregnancy rate are the other
benefits of this regimen.
HCG might also affect endometrial function, stimulate endometrial growth and maturation and
enhance the endometrial angiogenesis. These effects could extend the angiogenesis. These
results could lengthen the implantation Window.
Inhibin A is a heterodimer protein and does not begin to increase until just after the
increase in oestradiol in the late follicular phase, suggesting secretion by the dominant
follicle. Inhibin A secretion is regulated by LH and is associated with paracrine/autocrine
action on oocyte maturation. Moreover, it is related to follicular development and size,
serving as a marker of follicular maturation after IVF cycles .However, the role of hCG
supplementation during COH (controlled ovarian hyperstimulation)is still a matter of debate
and more studies is needed. Thus, the objective of this trial was to investigate whether LH
activity in the form of low dose hCG in GnRH (Gonadotropin releasing hormone)antagonist
cycles would improve the quality of oocytes, level of inhibin A and endometrial vascularity.
Status | Completed |
Enrollment | 60 |
Est. completion date | January 2015 |
Est. primary completion date | October 2014 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 20 Years to 40 Years |
Eligibility |
Inclusion Criteria: 1. Indication for ICSI treatment. 2. The presence of one or two functional ovaries. 3. Good responders to ovarian stimulation. 4. The presence of normal uterine cavity 5. Basal (day 2 or 3) serum FSH (follicle stimulating Hormone) levels =13 IU 6. No untreated endocrinologic disease Exclusion Criteria: 1. Abnormal uterine cavity. 2. Basal (day 2 or 3) serum FSH levels =13 IU. 3. Poor responders to ovarian stimulation according to the existence of at least two of the following criteria:Advanced maternal age (above 40 years), antral follicles count <5, prior history of poor response to controlled ovarian hyperstimulation (peak E2 <500 pg/ml and/or =3 oocytes retrieved). 4. Untreated endocrinologic disease. 5. Azoospermia. all patients should be managed in Cairo,Egypt |
Country | Name | City | State |
---|---|---|---|
Egypt | Cairo University | Cairo |
Lead Sponsor | Collaborator |
---|---|
Cairo University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Serum level of inhibin A | 9 months | ||
Primary | Number of oocytes | 9 months | ||
Primary | Pregnancy rate | 11months | ||
Secondary | Cost of antagonist treatment | 9 months | ||
Secondary | Spiral artery Doppler indices | Spiral artery Doppler indices are taken as a marker of subendometrial vascularity.The lowest resistance will be the better vascularity | 9 months | |
Secondary | The percentage of the perifollicular vascularity using power doppler | The percentage of the perifollicular vascularity (<25%,25-50%,%0%-75%,>75%) as a marker of the quality of the oocytes.The more vascularity the better quality | 9 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A | |
Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A | |
Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A | |
Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A | |
Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A |